Meanwhile, US obesity rates, which peaked in 2022 at 39.9%, fell further to 36.4%, suggesting, although not proving, a causal link
Federal deal could make popular GLP-1 drugs more affordable for millions of Americans As demand for Ozempic, Wegovy and Zepbound grows, local patients say cost remains the biggest barrier As demand for Ozempic, Wegovy and Zepbound grows, local patients say cost remains the biggest barrier CINCINNATI GLP-1 medications like Ozempic, Wegovy and Zepbound have become some of the most in-demand prescriptions in the country, helping people lose weight and improve their overall health
While traditional weight loss strategies are less effective in this case, newly developed, promising GLP-1 Receptor Agonist medications, the most famous being Ozempic , give hope to addressing underlying metabolic issues
Nutritionists, dermatologists, pharmaceutical formulators, procurement leaders from nutraceutical firms, developers of cosmetic products, food and beverage R&D managers, and buying managers from pharmacies, health stores, and online retailers were among the demand-side sources